Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-09, Stock:NVS, The news for the past five days is as follows:
2019-04-02: NEWS1: Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe.NEWS2: Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe.NEWS3: Novartis Gets Approval for Psoriasis Drug Cosentyx in China.NEWS4: Novartis Gets Approval for Psoriasis Drug Cosentyx in China.NEWS5: Novartis Gets Approval for Psoriasis Drug Cosentyx in China.NEWS6: Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe.NEWS7: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial.
2019-04-03: NEWS1: Biogen SMA drug price, Novartis estimates for its treatment far too high: U.S. group.NEWS2: Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group.NEWS3: Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group.NEWS4: Roche Extends Offer Period for Spark Therapeutics Acquisition.NEWS5: Roche Extends Offer Period for Spark Therapeutics Acquisition.NEWS6: Allergan's AMD Drug Lowers Inflammation in Phase III Study.NEWS7: Allergan's AMD Drug Lowers Inflammation in Phase III Study.NEWS8: After inking lease with cancer-fighting company, this new East Bay biotech project is full.NEWS9: Allergan's AMD Drug Lowers Inflammation in Phase III Study.NEWS10: Roche Extends Offer Period for Spark Therapeutics Acquisition.NEWS11: The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings.NEWS12: Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI.
2019-04-04: NEWS1: Novartis, Amgen in dispute over migraine drug partnership.NEWS2: Top Analyst Reports for Amazon, 3M & Novartis.NEWS3: Top Analyst Reports for Amazon, 3M & Novartis.NEWS4: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS5: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS6: 1 Biotech That Biogen Should Buy ... but Probably Won&apos;t.NEWS7: Top Analyst Reports for Amazon, 3M & Novartis.NEWS8: Achillion Meets Enrollment Target in Kidney Disease Studies.NEWS9: Achillion Meets Enrollment Target in Kidney Disease Studies.NEWS10: Novartis Resubmits BLA to FDA for Biosimilar of Neulasta.NEWS11: Novartis Resubmits BLA to FDA for Biosimilar of Neulasta.NEWS12: Novartis sues Amgen over migraine treatment Aimovig.NEWS13: Achillion Meets Enrollment Target in Kidney Disease Studies.NEWS14: Novartis Resubmits BLA to FDA for Biosimilar of Neulasta.NEWS15: Novartis CEO&apos;s $50 Billion of Deals Was Just the First Act.
2019-04-05: NEWS1: Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig.NEWS2: Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig.NEWS3: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS4: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS5: The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI.NEWS6: The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI.NEWS7: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU.NEWS8: Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig.NEWS9: Novartis Lawsuit Accuses Amgen Of Trying To Welsh On Migraine Deal.NEWS10: The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI.NEWS11: The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership.
2019-04-08: NEWS1: Eye-Care Leader Alcon Is About to Hit the Stock Market.NEWS2: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS3: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS4: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS5: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS6: Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym.NEWS7: The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca.NEWS8: Lawsuit over migraine deal could be good for Amgen, analysts say.NEWS9: Why Amgen's Giving Novartis a Headache.NEWS10: Why Amgen's Giving Novartis a Headache.

Answer: Decrease